Navigation Links
Alzheimer's Research May Lead to Preventing the Debilitating Disease
Date:12/3/2009

NEW YORK, Dec. 3 /PRNewswire/ -- Alzheimer's disease (AD) is one of the most heartbreaking diagnoses a person can receive. This irreversible, progressive brain disease slowly destroys memory and thinking skills and eventually even the ability to carry out the simplest tasks. The most common cause of dementia among older people, AD affects as many as 2.4 million to 4.5 million Americans, according to the National Institute on Aging.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/NY99197LOGO )

Jin Ryoun Kim, assistant professor of chemical and biological engineering at Polytechnic Institute of New York University, has been leading a team of researchers including Paramjit Arora, associate professor in NYU's Department of Chemistry; Mary Cowman, professor in NYU-Poly's Department of Chemical and Biological Science, and Jorge Ghiso, NYU School of Medicine associate professor, to make this debilitating disease a thing of the past.

Kim is interested in developing a biochemical probe that would quickly and quantitatively reveal toxic proteins associated with Alzheimer's. Developing an early, reliable diagnostic tool will enable researchers to develop drug-like compounds to prevent the disease.

What triggers Alzheimer's, Kim explains, is protein aggregation, in which a protein molecule sticks to neighboring identical molecules, ending up as a toxic form that interferes with normal brain functioning. While all humans have these protein molecules, young people's bodies are able to prevent accumulation of toxic forms of the protein. But as people age, they become more vulnerable to their effects.

Toxic molecules generated during the aggregation process have been directly linked to the onset of Alzheimer's. Unfortunately, the toxic molecule is difficult to detect: It's very unstable, and can change shape, structure or biological effect easily and rapidly.

"One of the biggest problems in AD research is the instability of these toxic protein forms," Kim says. "It's very likely that any existing method of finding them might be misleading; that is, it's like going after a moving target. Detection must be very rapid, specific and quantitative, but there's no such method yet."

That's where his research comes in. "We're trying to develop a biochemical compound -- a specific, rapid and quantitative probe -- that can detect the toxic protein molecule and report its presence quantitatively right away," he says. If such a probe can be developed, it could be used to identify drug-like compounds that can prevent the formation of toxic protein forms, and thus prevent the disease itself. The research is being conducted under a two-year $80,000 New Investigator Research Grant from the Alzheimer's Association (www.alz.org). Kim has filed for a provisional patent, based on preliminary data, for a biochemical probe that would quickly and quantitatively reveal toxic proteins associated with Alzheimer's.

"The goal of our research is a world without Alzheimer's disease," says Kim. "If there's no Alzheimer's in the world, maybe I'd have nothing to do, but it's something I wish. Hopefully, using our probe, maybe a solution is just a few years away."

About Polytechnic Institute of New York University

Polytechnic Institute of New York University (formerly Polytechnic University), an affiliate of New York University, is New York's most comprehensive school of engineering, applied sciences, technology and research, and is rooted in Polytechnic's 155-year tradition of invention, innovation and entrepreneurship -- i-squared-e.

The institution, founded in 1854, is one of the nation's oldest private engineering schools. In addition to its main campus at MetroTech Center in downtown Brooklyn, it offers programs at sites throughout the region and around the globe. NYU-Poly has centers in Long Island, Manhattan and Westchester County; globally, it has programs in Israel, China and will be an integral part of NYU's campus in Abu Dhabi opening in autumn 2010.

For more information, visit www.poly.edu.

SOURCE Polytechnic Institute of New York University


'/>"/>
SOURCE Polytechnic Institute of New York University
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
(Date:8/7/2017)... 7, 2017  Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... CareAcademy, ... that it has raised $1.675 M in seed funding to further expand its ... and Techstars Venture Capital Fund are the company’s primary investors. , ...
(Date:8/17/2017)... ... , ... Centrifugation is more than just spinning. Like a car in our ... do without. And just like a car, there are a few points to consider ... will learn about the most important safety aspects while using a centrifuge, as well ...
(Date:8/16/2017)... ... , ... The next Patient Care Academy at Kalamazoo Valley Community College begins ... the seven-week long Patient Care Academy are eligible to take the State of Michigan ... CNA in Kalamazoo is $24,428.* , As a CNA, one is equipped for employment ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , ... development, today announced Cumberland Skin Surgery and Dermatology has joined the ... offices in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin ...
Breaking Medicine News(10 mins):